CNTB — Topline Data Report from Seabreeze STAT COPD Study
Jun 30, 2026, 12:00:00 AM UTC
Summary
Connect Biopharma is set to report topline data from its Phase 2 Seabreeze STAT COPD study evaluating rademikibart for treating acute exacerbations in COPD on June 30, 2026. The study aims to assess the safety and efficacy of rademikibart as an adjunct to standard care, focusing on patients with type 2 inflammation. This study is part of Connect Biopharma's broader commitment to developing innovative treatments for respiratory diseases, addressing a significant unmet need in the management of COPD.
Company
CONNECT BIOPHARMA HOLDINGS LTD (CNTB)NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.connectbiopharm.comSimilar Events
Connect Biopharma to report Phase 2 Seabreeze STAT Asthma topline data
Connect Biopharma Holdings plans to announce topline results from its Phase 2 Seabreeze STAT Asthma study of rademikibart in the first half of 2026. The trial evaluates rademikibart, a monoclonal antibody, as an adjunct to standard of care for acute asthma exacerbations in adults and adolescents with type 2 inflammation. The primary endpoint is treatment failure rate over 28 days post-exacerbation. Rademikibart is being developed as a potential first-in-class biologic for acute asthma exacerbations, a setting with significant unmet need.
clinical readoutData Reporting from Rademikibart Phase 2 Trials
Connect Biopharma expects to report data from the Phase 2 trials of rademikibart in the first half of 2026, focusing on its efficacy in treating acute exacerbations.
clinical readoutPhase 2 Clinical Trial Top-Line Data Release for Severe Asthma
Top-line data from Upstream Bio's ongoing Phase 2 clinical trial in severe asthma is expected in the second half of 2026, furthering the development of verekitug.
clinical readoutTopline Data Readout for Phase 2b CORAL Trial
Topline data from the Phase 2b CORAL trial in IPF patients with chronic cough is expected in the second quarter of 2025, following completion of enrollment in February 2025.
clinical readout